C4 Therapeutics (CCCC) Change in Accured Expenses (2019 - 2026)

C4 Therapeutics has reported Change in Accured Expenses for 8 years, with the latest figure at -$3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 47.67% year-over-year to -$3.5 million; the trailing twelve-month figure through Mar 2026 stood at -$2.8 million (down 750.6% YoY), and the FY2025 full-year result was -$6.0 million, down 377.43% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.5 million, down from $2.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.2 million in Q4 2023, with the low at -$7.7 million in Q1 2024.
• Average Change in Accured Expenses over 5 years is -$261117.6, with a median of $537000.0 recorded in 2023.
• Peak annual rise in Change in Accured Expenses reached 669.17% in 2024, while the deepest fall reached 426.07% in 2024.
• Tracing CCCC's Change in Accured Expenses over 5 years: stood at $2.7 million in 2022, then soared by 92.5% to $5.2 million in 2023, then retreated by 23.29% to $4.0 million in 2024, then plunged by 47.95% to $2.1 million in 2025, then slumped by 270.23% to -$3.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.5 million (Q1 2026), $2.1 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.

Peer Comparison